Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia

A composition and drug technology, applied in the direction of drug combination, sugar-coated pills, pill delivery, etc., can solve the problem of undeveloped compound drugs containing olmesartan medoxomil, amlodipine and rosuvastatin

Active Publication Date: 2021-12-17
DAEWOONG PHARM CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] As described above, a combination drug containing olmesartan medoxomil and amlodipine and a combination drug containing olmesartan medoxomil and rosuvastatin have been developed, but so far no combination drug containing olmesartan medoxomil, amlodipine, and rosuvastatin has been developed. Combinations of Suvastatin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
  • Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
  • Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0072] Hereinafter, the present invention will be described in more detail in the following examples. However, the following examples merely illustrate the contents of the present invention and do not limit the scope of rights of the present invention. According to the detailed description and examples of the present invention, it should be understood that the content that can be easily deduced by those skilled in the art of the present invention belongs to the right scope of the present invention.

preparation example

[0074] Preparation of olmesartan / amlodipine bilayer tablet and rosuvastatin bilayer tablet

[0075] Olmesartan medoxomil / amlodipine besylate compartment (mixture) and rosuvastatin calcium compartment (mixture) were prepared according to the composition and typical method in the table below.

[0076] A composite bilayer tablet was prepared using a bilayer tablet machine, including an olmesartan medoxomil / amlodipine compartment (the first layer) and a rosuvastatin calcium compartment (the second layer).

experiment example 1

[0078] Experimental Example 1: Dissolution Test

[0079] The formulations prepared according to the preparation examples of the present invention were subjected to a comparative dissolution test under the following dissolution test conditions.

[0080] As control drugs used in the comparative dissolution test, Sevikar™ 10 / 40 mg tablet (amlodipine besylate / olmesartan medoxomil) and Crestrot™ 20 mg tablet (rosuvastatin calcium) were used.

[0081] Sevikar™ tablets and Crestrotm tablets are in the form of film-coated single tablets. SevikarTM tablets include silicified microcrystalline cellulose, pregelatinized starch, croscarmellose sodium and magnesium stearate as excipients, and include polyvinyl alcohol, macrogol 3350, titanium dioxide, talc and Iron oxide was used as a film coating agent.

[0082] Meanwhile, metronidazole tablets include microcrystalline cellulose, lactose hydrate, tricalcium phosphate, crospovidone, and magnesium stearate as excipients, and include hyprom...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, compartments containing a drug are formulated in separate forms so as to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent medicine can be obtained when compared to conventional single medicine.

Description

technical field [0001] The invention relates to a single-dosage pharmaceutical composition for treating hypertension and hyperlipidemia. Background technique [0002] Due to the large number of patients with hypertension and hyperlipidemia, many patients are simultaneously prescribed drugs for treating hypertension and hyperlipidemia. Since it is advantageous to prescribe a single dosage form to the patient, for example, Caduetan (Caduet TM ) is a compound drug of atorvastatin (atorvastatin) and amlodipine (amlodipine), which is being prescribed to patients as a compound drug for the treatment of hypertension and hyperlipidemia. [0003] Olmesartan medoxomil is an excellent angiotensin II receptor blocker (Angiotensin II receptor blocker ARB), known to be used as a drug for treating or preventing hypertension, heart disease, etc. Olmesartan medoxomil is currently sold under the trade name Olmetec TM sell. [0004] Amlodipine is a calcium channel blocker (Calcium Channel ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/24A61K9/48A61K9/20A61K9/28A61K31/4178A61K31/4422A61K31/505A61P9/12
CPCA61P9/12A61K31/4178A61K31/4422A61K31/505A61P3/06A61K9/209A61K9/284A61K9/2009A61K2300/00A61K9/4808A61K9/205A61K9/2027A61K9/2077
Inventor 金智娟金甫勳
Owner DAEWOONG PHARM CO LTD